- Global Operation
- Contract Manufacturing
The mechanism of the clinical antitumor action of Gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor
(EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.
Gefitinib is indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies. The effectiveness of Gefitinib is based on objective response rates.
GenibÂ® Tablet 250 mg: Each commercial box contains 30 tablets in Alu-Alu blister pack.